Bromodomains: Structure, function and pharmacology of inhibition

被引:168
作者
Ferri, Elena [1 ]
Petosa, Carlo [2 ,3 ,4 ]
McKenna, Charles E. [1 ]
机构
[1] Univ So Calif, Dept Chem, Dana & David Dornsife Coll Letters Arts & Sci, Univ Pk Campus, Los Angeles, CA 90089 USA
[2] Univ Grenoble Alpes, Inst Biol Struct, 71 Ave Martyrs, F-38044 Grenoble, France
[3] CNRS, IBS, F-38044 Grenoble, France
[4] Commissariat Energie Atom & Energies Alternat, IBS, F-38044 Grenoble, France
关键词
Bromodomains; Acetylated histones; BET proteins; Epigenetic drugs; Drug discovery; SMALL-MOLECULE INHIBITORS; FRAGMENT-BASED DISCOVERY; TRANSCRIPTIONAL ACTIVITY; CBP/P300; BROMODOMAIN; SELECTIVE-INHIBITION; SYNERGISTIC ACTIVITY; DISPLACEMENT ASSAYS; EPIGENETIC READERS; DRUG DISCOVERY; CHEMICAL PROBE;
D O I
10.1016/j.bcp.2015.12.005
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Bromodomains are epigenetic readers of histone acetylation involved in chromatin remodeling and transcriptional regulation. The human proteome comprises 46 bromodomain-containing proteins with a total of 61 bromodomains, which, despite highly conserved structural features, recognize a wide array of natural peptide ligands. Over the past five years, bromodomains have attracted great interest as promising new epigenetic targets for diverse human diseases, including inflammation, cancer, and cardiovascular disease. The demonstration in 2010 that two small molecule compounds, JQ1 and I-BET762, potently inhibit proteins of the bromodomain and extra-terminal (BET) family with translational potential for cancer and inflammatory disease sparked intense efforts in academia and pharmaceutical industry to develop novel bromodomain antagonists for therapeutic applications. Several BET inhibitors are already in clinical trials for hematological malignancies, solid tumors and cardiovascular disease. Currently, the field faces the challenge of single-target selectivity, especially within the BET family, and of overcoming problems related to the development of drug resistance. At the same time, new trends in bromodomain inhibitor research are emerging, including an increased interest in non-BET bromodomains and a focus on drug synergy with established antitumor agents to improve chemotherapeutic efficacy. This review presents an updated view of the structure and function of bromodomains, traces the development of bromodomain inhibitors and their potential therapeutic applications, and surveys the current challenges and future directions of this vibrant new field in drug discovery. (C) 2015 Elsevier Inc. All rights reserved.
引用
收藏
页码:1 / 18
页数:18
相关论文
共 169 条
[71]   Histone modifications: Combinatorial complexity or cumulative simplicity? [J].
Henikoff, S .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2005, 102 (15) :5308-5309
[72]   Optimization of 3,5-Dimethylisoxazole Derivatives as Potent Bromodomain Ligands [J].
Hewings, David S. ;
Fedorov, Oleg ;
Filippakopoulos, Panagis ;
Martin, Sarah ;
Picaud, Sarah ;
Tumber, Anthony ;
Wells, Christopher ;
Olcina, Monica M. ;
Freeman, Katherine ;
Gill, Andrew ;
Ritchie, Alison J. ;
Sheppard, David W. ;
Russell, Angela J. ;
Hammond, Ester M. ;
Knapp, Stefan ;
Brennan, Paul E. ;
Conway, Stuart J. .
JOURNAL OF MEDICINAL CHEMISTRY, 2013, 56 (08) :3217-3227
[73]   3,5-Dimethylisoxazoles Act As Acetyl-lysine-mimetic Bromodomain Ligands [J].
Hewings, David S. ;
Wang, Minghua ;
Philpott, Martin ;
Fedorov, Oleg ;
Uttarkar, Sagar ;
Filippakopoulos, Panagis ;
Picaud, Sarah ;
Vuppusetty, Chaitanya ;
Marsden, Brian ;
Knapp, Stefan ;
Conway, Stuart J. ;
Heightman, Tom D. .
JOURNAL OF MEDICINAL CHEMISTRY, 2011, 54 (19) :6761-6770
[75]   Identification of a Primary Target of Thalidomide Teratogenicity [J].
Ito, Takumi ;
Ando, Hideki ;
Suzuki, Takayuki ;
Ogura, Toshihiko ;
Hotta, Kentaro ;
Imamura, Yoshimasa ;
Yamaguchi, Yuki ;
Handa, Hiroshi .
SCIENCE, 2010, 327 (5971) :1345-1350
[76]   p300/CBP and cancer [J].
Iyer, NG ;
Özdag, H ;
Caldas, C .
ONCOGENE, 2004, 23 (24) :4225-4231
[77]   Structure and function of a human TAFII250 double bromodomain module [J].
Jacobson, RH ;
Ladurner, AG ;
King, DS ;
Tjian, R .
SCIENCE, 2000, 288 (5470) :1422-1425
[78]   A novel BET bromodomain inhibitor, RVX-208, shows reduction of atherosclerosis in hyperlipidemic ApoE deficient mice [J].
Jahagirdar, Ravi ;
Zhang, Haiyan ;
Azhar, Salman ;
Tobin, Jennifer ;
Attwell, Sarah ;
Yu, Raymond ;
Wu, Jin ;
McLure, Kevin G. ;
Hansen, Henrik C. ;
Wagner, Gregory S. ;
Young, Peter R. ;
Srivastava, Rai Ajit K. ;
Wong, Norman C. W. ;
Johansson, Jan .
ATHEROSCLEROSIS, 2014, 236 (01) :91-100
[79]   Translating the histone code [J].
Jenuwein, T ;
Allis, CD .
SCIENCE, 2001, 293 (5532) :1074-1080
[80]   A Plasmodium Falciparum Bromodomain Protein Regulates Invasion Gene Expression [J].
Josling, Gabrielle A. ;
Petter, Michaela ;
Oehring, Sophie C. ;
Gupta, Archna P. ;
Dietz, Olivier ;
Wilson, Danny W. ;
Schubert, Thomas ;
Laengst, Gernot ;
Gilson, Paul R. ;
Crabb, Brendan S. ;
Moes, Suzette ;
Jenoe, Paul ;
Lim, Shu Wei ;
Brown, Graham V. ;
Bozdech, Zbynek ;
Voss, Till S. ;
Duffy, Michael F. .
CELL HOST & MICROBE, 2015, 17 (06) :741-751